[Federal Register Volume 66, Number 219 (Tuesday, November 13, 2001)]
[Notices]
[Pages 56860-56862]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-28264]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA #223P]


Controlled Substances: Proposed Aggregate Production Quotas for 
2002

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed year 2002 aggregate production quotas.

-----------------------------------------------------------------------

SUMMARY: This notice proposes initial year 2002 aggregate production 
quotas for controlled substances in Schedules I and II of the 
Controlled Substances Act (CSA).

DATES: Comments or objections must be received on or before December 4, 
2001.

ADDRESSES: Send comments or objections to the Administrator, Drug 
Enforcement Administration, Washington, DC 20537, Attn.: DEA Federal 
Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and 
Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, DC 20537, Telephone: (202) 307-7183

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) 
requires that the Attorney General establish aggregate production 
quotas for each basic class of controlled substance listed in Schedules 
I and II. This responsibility has been delegated to the Administrator 
of the DEA by section 0.100 of Title 28 of the Code of Federal 
Regulations.
    The proposed year 2002 aggregate production quotas represent those 
quantities of controlled substances that may be produced in the United 
States in 2002 to provide adequate supplies of each substance for: the 
estimated medical, scientific, research, and industrial needs of the 
United States; lawful export requirements; and the establishment and 
maintenance of reserve stocks. These quotas do not include imports of 
controlled substances for use in industrial processes.
    In determining the proposed year 2002 aggregate production quotas, 
the Administrator considered the following factors: total actual 2000 
and estimated 2001 and 2002 net disposals of each substance by all 
manufacturers; estimates of 2001 year-end inventories of each substance 
and of any substance manufactured from it and trends in accumulation of 
such inventories; product development requirements of both bulk and 
finished dosage form manufacturers; projected demand as indicated by 
procurement quota applications filed pursuant to section 1303.12 of 
Title 21 of the Code of Federal Regulations; and other pertinent 
information.
    Pursuant to section 1303 of Title 21 of the Code of Federal 
Regulations, the Administrator of the DEA will, in early 2002, adjust 
aggregate production quotas and individual manufacturing quotas 
allocated for the year based upon 2001 year-end inventory and actual 
2001 disposition data supplied by quota recipients for each basic class 
of Schedule I or II controlled substance.

[[Page 56861]]

    Therefore, under the authority vested in the Attorney General by 
section 306 of the CSA of 1970 (21 U.S.C. 826), and delegated to the 
Administrator of the DEA by Section 0.100 of Title 28 of the Code of 
Federal Regulations, the Administrator hereby proposes that the year 
2002 aggregate production quotas for the following controlled 
substances, expressed in grams of anhydrous acid or base, be 
established as follows:

------------------------------------------------------------------------
                                                              Proposed
                        Basic class                           year 2002
                                                               quotas
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
2,5-Dimethoxyamphetamine..................................    12,501,000
2,5-Dimethoxy-4-ethylamphetamine (DOET)...................             2
3-Methylfentanyl..........................................             4
3-Methylthiofentanyl......................................             2
3,4-Methylenedioxy-amphetamine (MDA)......................            15
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)..............            15
3,4-Methylenedioxy-methamphetamine (MDMA).................            15
3,4,5-Trimethoxyamphetamine...............................             2
4-Bromo-2,5-Dimethoxyamphetamine (DOB)....................             2
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB)................             2
4-Methoxyamphetamine......................................             7
4-Methylaminorex..........................................             2
4-Methyl-2,5-Dimethoxyamphetamine (DOM)...................             2
5-Methoxy-3,4-Methylene-dioxyamphetamine..................             2
Acetyl-alpha-methylfentanyl...............................             2
Acetyldihydrocodeine......................................             2
Acetylmethadol............................................             2
Allylprodine..............................................             2
Alphacetylmethadol........................................             7
Alpha-ethyltryptamine.....................................             2
Alphameprodine............................................             2
Alphamethadol.............................................             2
Alpha-methylfentanyl......................................             2
Alpha-methylthiofentanyl..................................             2
Aminorex..................................................             7
Benzylmorphine............................................             2
Betacetylmethadol.........................................             2
Beta-hydroxy-3-methylfentanyl.............................             2
Beta-hydroxyfentanyl......................................             2
Betameprodine.............................................             2
Betamethadol..............................................             2
Betaprodine...............................................             2
Bufotenine................................................             2
Cathinone.................................................             9
Codeine-N-oxide...........................................             2
Diethyltryptamine.........................................             2
Difenoxin.................................................         9,000
Dihydromorphine...........................................     1,101,000
Dimethyltryptamine........................................             3
Gamma-hydroxybutyric acid.................................             7
Heroin....................................................             2
Hydroxypethidine..........................................             2
Lysergic acid diethylamide (LSD)..........................            46
Marihuana.................................................       715,000
Mescaline.................................................             7
Methaqualone..............................................             9
Methcathinone.............................................             9
Morphine-N-oxide..........................................             2
N,N-Dimethylamphetamine...................................             7
N-Ethyl-1-Phenylcyclohexylamine (PCE).....................             5
N-Ethylamphetamine........................................             7
N-Hydroxy-3,4-Methylene-dioxyamphetamine..................             2
Noracymethadol............................................             2
Norlevorphanol............................................             2
Normethadone..............................................             7
Normorphine...............................................             7
Para-fluorofentanyl.......................................             2
Pholcodine................................................             2
Propiram..................................................       415,000
Psilocybin................................................             2
Psilocyn..................................................             2
Tetrahydrocannabinols.....................................       131,000
Thiofentanyl..............................................             2
Trimeperidine.............................................             2
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine...................................            12
1-Piperidinocyclo-hexanecarbonitrile (PCC)................            10
Alfentanil................................................           672
Alphaprodine..............................................             2
Amobarbital...............................................       451,000
Amphetamine...............................................    13,964,000
Carfentanil...............................................           120
Cocaine...................................................       251,000
Codeine (for sale)........................................    38,901,000
Codeine (for conversion)..................................    59,051,000
Dextropropoxyphene........................................   126,001,000
Dihydrocodeine............................................       376,000
Diphenoxylate.............................................       401,000
Ecgonine..................................................        51,000
Ethylmorphine.............................................            12
Fentanyl..................................................       440,000
Glutethimide..............................................             2
Hydrocodone (for sale)....................................    23,825,000
Hydrocodone (for conversion)..............................    13,500,000
Hydromorphone.............................................     1,409,000
Isomethadone..............................................            12
Levo-alphacetylmethadol (LAAM)............................            12
Levomethorphan............................................             2
Levorphanol...............................................        37,000
Meperidine................................................     9,479,000
Metazocine................................................             1
Methadone (for sale)......................................    12,705,000
Methadone Intermediate....................................    18,004,000
Methamphetamine...........................................     2,315,000
325,000 grams of levo-desoxyephedrine for use in a non-
 controlled, non-prescription product; 1,950,000 grams for
 methamphetamine for conversion to a Schedule III product;
 and 40,000 grams for methamphetamine (for sale)
Methylphenidate...........................................    17,618,000
Morphine (for sale).......................................    15,615,000
Morphine (for conversion).................................   110,774,000
Nabilone..................................................             2
Noroxymorphone (for sale).................................        25,000
Noroxymorphone (for conversion)...........................     6,000,000
Opium.....................................................       500,000
Oxycodone (for sale)......................................    40,109,000
Oxycodone (for conversion)................................       311,000
Oxymorphone...............................................       204,000
Pentobarbital.............................................    27,728,000
Phencyclidine.............................................            21
Phenmetrazine.............................................             2
Phenylacetone.............................................       801,000
Secobarbital..............................................             2
Sufentanil................................................         1,700
Thebaine..................................................    59,090,000
------------------------------------------------------------------------

    The Administrator further proposes that aggregate production quotas 
for all other Schedules I and II controlled substances included in 
sections 1308.11 and 1308.12 of Title 21 of the Code of Federal 
Regulations be established at zero.
    All interested persons are invited to submit their comments and 
objections in writing regarding this proposal. A person may object to 
or comment on the proposal relating to any of the above-mentioned 
substances without filing comments or objections regarding the others. 
If a person believes that one or more of these issues warrant a 
hearing, the individual should so state and summarize the reasons for 
this belief.
    In the event that comments or objections to this proposal raise one 
or more issues which the Administrator finds warrant a hearing, the 
Administrator shall order a public hearing by notice in the Federal 
Register, summarizing the issues to be heard and setting the time for 
the hearing.
    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866.
    This action does not preempt or modify any provision of state law; 
nor does it impose enforcement responsibilities on any state; nor does 
it diminish the power of any state to enforce its own laws. 
Accordingly, this action does not have federalism implications 
warranting the application of Executive Order 13132.
    The Administrator hereby certifies that this action will have no 
significant impact upon small entities whose interests must be 
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. 
The establishment of aggregate production quotas for Schedules I and II 
controlled substances is mandated by law and by international treaty 
obligations. The quotas are necessary to provide for the estimated 
medical, scientific, research and industrial needs of the United 
States, for export

[[Page 56862]]

requirements and the establishment and maintenance of reserve stocks. 
While aggregate production quotas are of primary importance to large 
manufacturers, their impact upon small entities is neither negative nor 
beneficial. Accordingly, the Administrator has determined that this 
action does not require a regulatory flexibility analysis.
    This action meets the applicable standards set forth in sections 
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
    This action will not result in the expenditure by State, local, and 
tribal governments, in the aggregate, or by the private sector, of 
$100,000,000 or more in any one year, and will not significantly or 
uniquely affect small governments. Therefore, no actions were deemed 
necessary under the provisions of the Unfunded Mandates Reform Act of 
1995.
    This action is not a major rule as defined by Section 804 of the 
Small Business Regulatory Enforcement Fairness Act of 1996. This action 
will not result in an annual effect on the economy of $100,000,000 or 
more; a major increase in costs or prices; or significant adverse 
effects on competition, employment, investment, productivity, 
innovation, or on the ability of United States-based companies to 
compete with foreign-based companies in domestic and export markets.
    The Drug Enforcement Administration makes every effort to write 
clearly. If you have suggestions as to how to improve the clarity of 
this regulation, call or write Frank L. Sapienza, Chief, Drug and 
Chemical Evaluation Section, Office of Diversion Control, Drug 
Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-
7183.

    Dated: November 6, 2001.
Asa Hutchinson,
Administrator.
[FR Doc. 01-28264 Filed 11-9-01; 8:45 am]
BILLING CODE 4410-09-P